Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abaxis Inc.

Latest From Kainos Medicine Inc.

Interview: Kainos Aims To Open New Era With Novel Parkinson’s Drug

Kainos Medicine’s senior vice president sat down with Scrip to talk about the progress and ambitions for its first-in-class, potentially disease modifying Parkinson's disease drug candidate. If the drug candidate successfully goes through a Phase IIa in the US, it is set to draw robust interest from multinational pharmas which are already active in the area that lacks fundamental treatments.

South Korea Research & Development

Ildong, Cellivery To Co-Develop Novel Biologic For Parkinson's

South Korean pharma firm Ildong and bioventure Cellivery have tied up to jointly develop an early stage, first-in-class therapy for Parkinson's disease using Cellivery's platform technology. The two hope the partnership will fundamentally change the therapeutic approach to the neurodegenerative disease.

BioPharmaceutical Asia Pacific

Novel Parkinson’s Therapy Moves Ahead Through Korea Deal

South Korean researchers have taken a step forward in developing a disease-modifying treatment for Parkinson's disease. Kainos Medicine has licensed in an innovative candidate for the now incurable disease, KR-33493, which is set for clinical trials in the country and is expected to be a first-in-class drug that can curb dopaminergic neuronal cell death.

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abaxis Inc.
  • Senior Management
  • Clinton H Severson, Chmn., Pres. & CEO
    Alberto R Santa Ines, VP, Fin. & CFO
    Kenneth P Aron, PhD, CTO
    Ross Taylor, VP, Bus. Dev. & Investor Relations
  • Contact Info
  • Abaxis Inc.
    Phone: (510) 675-6500
    3240 Whipple Rd.
    Union City, CA 94587